Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis
- PMID: 32588384
- PMCID: PMC7334327
- DOI: 10.1007/s40801-020-00201-y
Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis
Abstract
Objectives: Acute bacterial skin and soft tissue infections (ABSSSIs) are a leading cause of presentation to the emergency department (ED). This study aimed to determine the potential impact of utilizing oritavancin in the ED or observation unit (OBS) on hospital inpatient admission.
Methods: A single-center community teaching hospital developed a pharmacy-led pilot to evaluate the use of oritavancin as a measure to avoid hospital admissions/readmissions in appropriate patients with ABSSSIs. Prior to initiation of the oritavancin pilot, prespecified inclusion and exclusion criteria were determined for proper patient selection. The pilot ran from January 1 to December 31, 2017. The data were compared to corresponding data for an equal number of patients during the pilot period who had similar ABSSSI diagnoses to the oritavancin pilot group but received vancomycin. The primary outcome was length of stay (LOS), defined as the total time in hours from presentation to the ED until discharge home, including time spent in the OBS or inpatient unit.
Results: During the study period, 122 patients met the study criteria and 61 patients received oritavancin in the ED or OBS unit. These patients were compared to 61 consecutive patients during the pilot period who received vancomycin. Administration of oritavancin in the ED or OBS was associated with a significantly shorter mean LOS relative to the standard of care group (19.5 vs. 85.98 h, p < 0.01). All-cause 30-day readmissions were the same for both groups (6 vs. 6, p = 1).
Conclusions: These results suggest that use of oritavancin in the ED or OBS setting for ABSSSIs may shorten LOS without negatively affecting readmissions.
Conflict of interest statement
TL receives consulting and speaker fees from Melinta Therapeutics. SA, SB, BH, AM, and KR have no conflicts to declare.
Figures

Similar articles
-
Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations.Clin Ther. 2016 Jan 1;38(1):136-48. doi: 10.1016/j.clinthera.2015.11.014. Epub 2015 Dec 18. Clin Ther. 2016. PMID: 26708118
-
Modeling operational quality metrics and costs of long-acting antibiotics for acute bacterial skin and skin structure infection treatment in the emergency department.J Med Econ. 2019 Jul;22(7):652-661. doi: 10.1080/13696998.2019.1591423. Epub 2019 Apr 2. J Med Econ. 2019. PMID: 30838908
-
Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway.Drugs Real World Outcomes. 2020 Jun;7(Suppl 1):30-35. doi: 10.1007/s40801-020-00196-6. Drugs Real World Outcomes. 2020. PMID: 32588388 Free PMC article.
-
Use of lipoglycopeptides for moderate to severe ABSSSI in the emergency department.Am J Emerg Med. 2025 Jan;87:44-50. doi: 10.1016/j.ajem.2024.10.040. Epub 2024 Oct 26. Am J Emerg Med. 2025. PMID: 39489025 Review.
-
Oritavancin: a review in acute bacterial skin and skin structure infections.Drugs. 2015 Nov;75(16):1891-902. doi: 10.1007/s40265-015-0478-7. Drugs. 2015. PMID: 26464319 Review.
Cited by
-
Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties.Open Forum Infect Dis. 2022 Mar 23;9(5):ofac090. doi: 10.1093/ofid/ofac090. eCollection 2022 May. Open Forum Infect Dis. 2022. PMID: 35392455 Free PMC article.
-
The future approach for the management of acute bacterial skin and skin structure infections.Curr Opin Infect Dis. 2025 Apr 1;38(2):128-135. doi: 10.1097/QCO.0000000000001092. Epub 2025 Jan 15. Curr Opin Infect Dis. 2025. PMID: 39831591 Free PMC article. Review.
-
The role of long-acting antibiotics in the clinical practice: a narrative review.Infez Med. 2023 Dec 1;31(4):449-465. doi: 10.53854/liim-3104-4. eCollection 2023. Infez Med. 2023. PMID: 38075413 Free PMC article. Review.
-
Real-World Evidence Studies of Oritavancin Use in Gram-Positive Infections Augment Randomized Controlled Trials to Address Clinical and Economic Outcomes.Drugs Real World Outcomes. 2020 Jun;7(Suppl 1):2-5. doi: 10.1007/s40801-020-00189-5. Drugs Real World Outcomes. 2020. PMID: 32588383 Free PMC article.
-
[Defining new therapeutic scenarios for oritavancin: severe bacteremic Staphylococcus aureus skin and soft tissue infection in a severely immunocompromised oncology patient].Rev Esp Quimioter. 2023 Dec;36(6):645-647. doi: 10.37201/req/055.2023. Epub 2023 Oct 11. Rev Esp Quimioter. 2023. PMID: 37818986 Free PMC article. Spanish. No abstract available.
References
-
- Melinta Therapeutics. Prescribing information for Orbactiv (oritavancin). https://www.orbactiv.com/pdfs/orbactiv-prescribing-information.pdf.
-
- Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254–262. doi: 10.1093/cid/ciu778. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous